ICON Public FY2025 EPS Estimate Lowered by Leerink Partnrs

ICON Public Limited (NASDAQ:ICLR) – Analysts at Leerink Partnrs cut their FY2025 EPS estimates for ICON Public in a note issued to investors on Tuesday, November 19th. Leerink Partnrs analyst M. Cherny now anticipates that the medical research company will earn $14.11 per share for the year, down from their prior estimate of $14.58. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for ICON Public’s current full-year earnings is $13.42 per share. Leerink Partnrs also issued estimates for ICON Public’s FY2026 earnings at $15.94 EPS and FY2027 earnings at $17.95 EPS.

ICON Public (NASDAQ:ICLR) last released its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share for the quarter, missing the consensus estimate of $3.72 by ($0.37). The business had revenue of $2.03 billion during the quarter, compared to analysts’ expectations of $2.13 billion. ICON Public had a return on equity of 11.91% and a net margin of 9.00%. The company’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same quarter last year, the business posted $3.10 EPS.

Other equities research analysts have also issued research reports about the stock. StockNews.com lowered shares of ICON Public from a “buy” rating to a “hold” rating in a research note on Thursday, September 19th. Evercore ISI cut their price objective on ICON Public from $360.00 to $350.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Redburn Atlantic assumed coverage on ICON Public in a research report on Monday, October 14th. They issued a “neutral” rating and a $311.00 target price for the company. Truist Financial dropped their price target on ICON Public from $363.00 to $295.00 and set a “buy” rating on the stock in a research report on Monday, October 28th. Finally, TD Cowen reduced their price target on ICON Public from $369.00 to $285.00 and set a “buy” rating on the stock in a research note on Friday, October 25th. Four investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $292.45.

ICON Public Stock Performance

NASDAQ:ICLR opened at $214.25 on Thursday. The company has a quick ratio of 1.34, a current ratio of 1.34 and a debt-to-equity ratio of 0.35. The firm’s fifty day simple moving average is $257.93 and its 200 day simple moving average is $297.75. The stock has a market cap of $17.68 billion, a P/E ratio of 23.89, a price-to-earnings-growth ratio of 1.45 and a beta of 1.25. ICON Public has a twelve month low of $183.38 and a twelve month high of $347.72.

Hedge Funds Weigh In On ICON Public

A number of hedge funds have recently bought and sold shares of the company. Foyston Gordon & Payne Inc purchased a new position in ICON Public in the third quarter worth about $11,672,000. Liontrust Investment Partners LLP increased its position in shares of ICON Public by 19.5% during the second quarter. Liontrust Investment Partners LLP now owns 119,728 shares of the medical research company’s stock valued at $37,531,000 after acquiring an additional 19,546 shares in the last quarter. Kornitzer Capital Management Inc. KS raised its holdings in ICON Public by 15.9% in the 2nd quarter. Kornitzer Capital Management Inc. KS now owns 95,753 shares of the medical research company’s stock worth $30,016,000 after acquiring an additional 13,163 shares during the last quarter. Icon Wealth Advisors LLC lifted its position in ICON Public by 861.1% in the 3rd quarter. Icon Wealth Advisors LLC now owns 13,215 shares of the medical research company’s stock valued at $3,797,000 after acquiring an additional 11,840 shares in the last quarter. Finally, Sara Bay Financial purchased a new stake in ICON Public during the 3rd quarter valued at $1,143,000. Institutional investors own 95.61% of the company’s stock.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.